Fleur Breteau, a cancer patient and activist, has continued to express her frustration over political decisions related to pesticides, especially the law Duplomb, enacted by French senators in July 2025. This law has drawn criticism from Breteau, who directs her anger toward industrial agriculture and chemical companies, along with their political allies across the center, right, and far-right. Breteau is a key figure in the Cancer Colère movement, which has gained significant traction in recent months. The movement blends anger with a sense of empowerment, as participants share personal stories and challenge the existing structures that they believe contribute to the rising cancer rates. Breteau's activism began after her second cancer diagnosis and the death of a close friend from the disease at the age of 46. She has drawn attention to the law Duplomb, which she claims allows pesticide manufacturers to also produce cancer treatments. This connection, she argues, raises ethical concerns and highlights the need for transparency. She stresses the importance of sharing accurate, verifiable information to counter the idea that individuals are solely responsible for their illnesses. In France, cancer is the leading cause of medical spending, with costs exceeding 27 billion euros in 2023. In her book Cancer Colère, Breteau documents the experiences of cancer patients, including the emotional burden of self-blame, the physical and mental toll of treatment, and the financial instability that often follows a diagnosis. She argues that these personal stories reveal deeper systemic issues in healthcare, particularly the neglect of workers' health, with women being especially vulnerable due to less workplace protection. She also highlights the case of Laure Marivain, a florist who lost her daughter to leukemia after pesticide exposure during pregnancy. Breteau criticizes the lack of recognition of breast cancer as an occupational disease, pointing out that 97% of studies on occupational cancers focus on men or non-gender-specific populations, despite the fact that 90% of chemicals have hormonal effects that disproportionately affect women. While acknowledging that cancer can have multiple causes, including lifestyle and genetics, Breteau insists on the need to recognize the link between pesticides and disease. She cites the Conseil national de l'ordre des médecins, which has warned about the risks of pesticides, including neuro-developmental disorders and pediatric cancers. She also mentions Arnaud Rousseau, president of the FNSEA, who has accused the movement of creating an "hysteria" around pesticides, a claim reminiscent of those made against environmental writer Rachel Carson in the 1960s. Breteau is organizing a mobilization on October 3 against the multinational company Syngenta, uniting patients, farmers, healthcare workers, and others concerned about the health impacts of pesticides. The movement, she says, is moving beyond political and social divides, with a focus on public health, clean water, children's health, and access to healthcare. She emphasizes the power of personal stories in challenging the idea that cancer is an unavoidable part of life or that food sovereignty must depend on industrial agriculture and pesticides. She also calls for support for sustainable agricultural practices and public investment in farming that prioritizes health and the environment, urging solidarity between cancer patients, victims, and the farming community to challenge the current system and promote a healthier, more autonomous agricultural sector.